<?xml version="1.0" encoding="UTF-8"?>
<p id="para10">The global pandemic of severe acute respiratory coronavirus 2 (SARS-CoV-2), which causes coronavirus disease 2019 (COVID-19), continues to spread around the world, having infected more than 1·8 million people and causing over 100 000 deaths as of April 13, 2020. High-quality evidence showing the effectiveness of treatments for COVID-19 is scarce, but over 400 studies are now registered in 
 <ext-link ext-link-type="uri" xlink:href="http://ClinicalTrails.gov" id="interrefs30a" xmlns:xlink="http://www.w3.org/1999/xlink">ClinicalTrails.gov</ext-link> testing a range of therapies, including immunosuppressants and the anti-malarial drugs chloroquine and hydroxychloroquine. One therapy being tested is convalescent plasma, a type of passive antibody therapy, in which blood plasma is isolated from people who have recovered from the disease of interest and is administered to those with the disease to suppress viraemia and improve clinical symptoms.
</p>
